Cantargia
1.836
SEK
+0.44 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1,314 following
+0.44%
-4.18%
-38.35%
-51.04%
-51.3%
-50.88%
-52.01%
-87.41%
-86.04%
-74.02%
cantargia.com
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
1.81 / 1.858
SEK
Market cap
337.25M SEK
Turnover
320.77K SEK
Volume
175K
Latest videos
Financial calendar
Extraordinary general meeting
2024-12-02
Annual report
2025-02-21
Interim report
2025-05-13
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Fjärde AP-fonden | 9.9 % | 9.9 % |
| Första AP-Fonden | 7.1 % | 7.1 % |
| Alecta Pensionsförsäkring, Ömsesidigt | 7.0 % | 7.0 % |
| Six Sis AG | 4.7 % | 4.7 % |
| Försäkringsaktiebolaget, Avanza Pension | 4.4 % | 4.4 % |
| Goldman Sachs International | 3.4 % | 3.4 % |
| Handelsbanken fonder | 3.2 % | 3.2 % |
| Swedbank Robur Fonder | 2.0 % | 2.0 % |
| Brushamn Invest | 1.2 % | 1.2 % |
| Prioritet Finans | 1.1 % | 1.1 % |
ShowingAll content types
Cantargia, Audiocast with teleconference, Q3'24
Cantargia publishes interim report for third quarter 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Cantargia publicerar delårsrapport för tredje kvartalet 2024
Cantargia presenterar valberedning inför årsstämman 2025
Cantargia presents Nomination Committee ahead of 2025 AGM
Cantargia: resultat som visar effekt med CAN10 i modeller av hjärtmuskelinflammation publicerade i Circulation: Heart Failure
Cantargia results showing efficacy of CAN10 in models of myocarditis published in Circulation: Heart Failure
Finansinspektionen: Flaggningsmeddelande i CANTARGIA AB
